Clinical Trials on Alzheimer’s Disease Conference 2019: What to Look Out For
SAN DIEGO — Headlining a top Alzheimer’s conference this week, the pharmaceutical company Biogen will for the first time share the data that led…
SAN DIEGO — Headlining a top Alzheimer’s conference this week, the pharmaceutical company Biogen will for the first time share the data that led…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
Clinical trials and studies scientific experiments that investigate new treatments, lifestyle interventions, or risk factors for developing a disease like Alzheimer’s or dementia. By…
Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard…
As Dr. Jeff Chen MD, MBA recalled in a recent talk at the 2023 TED Conference in Vancouver, BC, when he was a medical…
Recently, Eli Lilly announced that their anti-amyloid drug solanezumab failed to prevent Alzheimer’s in cognitively healthy older individuals who showed amyloid plaque accumulation in…
With research for the recently FDA-approved Leqembi still in clinical trials and other Alzheimer’s research ongoing, many are considering whether to be a part…
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
While scientists don’t know yet what causes Alzheimer’s, beta-amyloid protein plaques remain one of the prime suspects. While many approaches have focused on clearing…
In February of this year, the Centers for Medicare and Medicaid Services (CMS) released a confusing proposal to dramatically limit insurance coverage for Aduhelm,…
Protollin, a new vaccine for Alzheimer’s that is administered nasally, heads to human clinical trials. Through the incredible power of our immune system, researchers…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
The toxic accumulation of four abnormal proteins in the brain is such a harbinger of cognitive decline, one researcher has taken to calling them…
Researchers at the Salk Institute for Biological Studies have reported that a drug candidate called CMS121 has successfully halted and possibly reversed memory loss in…
While pharmaceutical companies have invested decades of research and billions of dollars in the quest to cure to Alzheimer’s, more than 100 experimental therapies…